Positive phase III clinical trial data has supported the continuing development of a once-daily non-steroidal anti-inflammatory product for the treatment of ocular inflammation and pain following cataract surgery. The clinical study, sponsored by ISTA Pharmaceuticals, Inc., showed that Prolensa, a new modified ophthalmic NSAID formulation incorporating a lower concentration of bromphenac, met both primary and secondary endpoints with a statistically improved clearing of participants’ ocular inflammation by day 15. In addition, the data demonstrated that a greater proportion of study subjects were pain free one day after surgery compared with the placebo group.
New Drug Application tabled for Prolensa following positive phase III study in control of post-surgical inflammation
- by swdadmin